Brief: MeiraGTx collaborates with Hologen AI to expedite development of its Parkison's disease therapy, scale up manufacturing
13/03/2025 11:38
March 13 (Reuters) - MeiraGTx Holdings PLC MGTX.O: MEIRAGTX ENTERS INTO A STRATEGIC COLLABORATION WITH HOLOGEN AI TO EXPEDITE PHASE 3 DEVELOPMENT OF AAV-GAD FOR PARKINSON’S DISEASE AND INDUSTRIALIZE MEIRAGTX’S PROPRIETARY MANUFACTURING PROCESS MEIRAGTX HOLDINGS PLC - TO RECEIVE $200 MILLION IN UPFRONT CASH MEIRAGTX HOLDINGS PLC - TO RETAIN 30% OWNERSHIP IN JOINT VENTURE MEIRAGTX HOLDINGS PLC - JOINT VENTURE HOLOGEN NEURO AI LTD TO RECEIVE $230 MILLION Source text: ID:nGNX88BhqQ Further company coverage: MGTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MeiraGTx Holdings
See all newsU.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
MeiraGTx gains; reports over $200 mln in license revenue
MeiraGTx Holdings PLC reports results for the quarter ended June 30 - Earnings Summary
MeiraGTx Q2 revenue jumps on Reogen license revenue
Brief: Graviton Bioscience Announces Clearance Of Investigational New Drug For GV101 For Treatment Of Friedreich's Ataxia